Women, Hypertension, and the Systolic Blood Pressure Intervention Trial

详细信息    查看全文

• 作者：Nanette K. Wenger ; MD^a ; Keith C. Ferdinand ; MD^b ; C. Noel Bairey Merz ; MD^c ; Mary Norine Walsh ; MD^d ; Martha Gulati ; MD ; MS^e ; Carl J. Pepine ; MD^f ; ^{carl.pepine@medicine.ufl.edu" class="auth_mail" title="E-mail the corresponding author} ; for the American College of Cardiology Cardiovascular Disease in Women Committee
• 关键词：Adverse outcomes ; Blood pressure ; Cardiovascular disease ; Hypertension ; Intervention ; Level of evidence ; Sex-specific pathophysiology ; Systolic Blood Pressure Intervention Trial ; Treatment goals
• 刊名：The American Journal of Medicine
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：129
• 期：10
• 页码：1030-1036
• 全文大小：662 K

文摘

Hypertension accounts for approximately 1 in 5 deaths in American women and is the major contributor to many comorbid conditions. Although blood pressure lowering reduces cardiovascular disease outcomes, considerable uncertainty remains on best management in women. Specifically, female blood pressure treatment goals have not been established, particularly among older and African American and Hispanic women, for whom hypertension prevalence, related adverse outcomes, and poor control rates are high. The Systolic Blood Pressure Intervention Trial (SPRINT) planned to clarify optimal blood pressure management in both sexes. Although confirming that a lower blood pressure goal is generally better, because female enrollment and event rates were low and follow-up shortened, outcomes differences in women were not statistically significant. Thus optimal blood pressure goals for women have not been established with the highest evidence. This review addresses SPRINT's significance and key remaining knowledge gaps in optimal blood pressure management to improve women's health.